Chicken pox infection in a three months old infant exposed in utero to Adalimumab
| Autor: | Sara Avlund, Mette Julsgaard, Anne Grosen, Anna Johnsson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Necrosis Physiology Antibodies Monoclonal Humanized Immunocompromised Host Chickenpox Pregnancy Placenta medicine Adalimumab Humans biology business.industry Gastroenterology Infant General Medicine Environmental exposure medicine.disease medicine.anatomical_structure In utero Prenatal Exposure Delayed Effects Immunology biology.protein Tumor necrosis factor alpha Female Antibody medicine.symptom business Immunosuppressive Agents medicine.drug |
| Zdroj: | Johnsson, A, Avlund, S, Grosen, A & Julsgaard, M 2013, ' Chicken pox infection in a three months old infant exposed in utero to Adalimumab ', Journal of Crohn's & colitis, vol. 7, no. 3, pp. e116-7 . https://doi.org/10.1016/j.crohns.2012.07.020 |
| Popis: | Dear Sir, Observational data suggest that anti-tumor necrosis factor (TNF)-α antibodies such as Adalimumab (ADA) is safe in pregnancy and that there is no increase in adverse birth outcomes.1 It is believed that ADA efficiently crosses the placenta in the third trimester.1 Live virus vaccines are contraindicated in infants exposed to anti-TNF-α antibodies up to the age of one year, due to the risk of severe complications.1,2 However, environmental exposure of the infant to viruses cannot be eliminated. We present a case of an infant born preterm, exposed in uteri to ADA, who … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|